IIM
MCID: MYS005
MIFTS: 56

Myositis (IIM)

Categories: Bone diseases, Genetic diseases, Infectious diseases, Muscle diseases, Neuronal diseases, Rare diseases, Respiratory diseases, Skin diseases

Aliases & Classifications for Myositis

MalaCards integrated aliases for Myositis:

Name: Myositis 56 12 74 52 29 54 6 42 43 15 17 71 32
Idiopathic Inflammatory Myopathy 52 25 58
Idiopathic Inflammatory Myositis 52 25 58
Iim 56 52
Imm 52 58
Myopathy, Familial Idiopathic Inflammatory; Iim 56
Myopathy, Familial Idiopathic Inflammatory 56
Idiopathic Inflammatory Myopathy, Familial 52
Idiopathic Inflammatory Myopathies 25
Myopathies Idiopathic Inflammatory 54
Inflammatory Myopathy, Idiopathic 25
Inflammatory Disorder of Muscle 12

Characteristics:

OMIM:

56
Inheritance:
autosomal dominant


HPO:

31
myositis:
Inheritance autosomal dominant inheritance


Classifications:

Orphanet: 58  
Rare neurological diseases
Rare systemic and rhumatological diseases


External Ids:

Disease Ontology 12 DOID:633
OMIM 56 160750
MeSH 43 D009220
NCIt 49 C27578
SNOMED-CT 67 26889001
UMLS via Orphanet 72 C0751356
Orphanet 58 ORPHA98482
MedGen 41 C0027121
SNOMED-CT via HPO 68 128496001 249939004 263681008
UMLS 71 C0027121

Summaries for Myositis

Genetics Home Reference : 25 Idiopathic inflammatory myopathy is a group of disorders characterized by inflammation of the muscles used for movement (skeletal muscles). Idiopathic inflammatory myopathy usually appears in adults between ages 40 and 60 or in children between ages 5 and 15, though it can occur at any age. The primary symptom of idiopathic inflammatory myopathy is muscle weakness, which develops gradually over a period of weeks to months or even years. Other symptoms include joint pain and general tiredness (fatigue). There are several forms of idiopathic inflammatory myopathy, including polymyositis, dermatomyositis, and sporadic inclusion body myositis. Polymyositis and dermatomyositis involve weakness of the muscles closest to the center of the body (proximal muscles), such as the muscles of the hips and thighs, upper arms, and neck. People with these forms of idiopathic inflammatory myopathy may find it difficult to climb stairs, get up from a seated position, or lift items above their head. In some cases, muscle weakness may make swallowing or breathing difficult. Polymyositis and dermatomyositis have similar symptoms, but dermatomyositis is distinguished by a reddish or purplish rash on the eyelids, elbows, knees, or knuckles. Sometimes, abnormal calcium deposits form hard, painful bumps under the skin (calcinosis). In sporadic inclusion body myositis, the muscles most affected are those of the wrists and fingers and the front of the thigh. Affected individuals may frequently stumble while walking and find it difficult to grasp items. As in dermatomyositis and polymyositis, swallowing can be difficult.

MalaCards based summary : Myositis, also known as idiopathic inflammatory myopathy, is related to inclusion body myositis and myositis fibrosa, and has symptoms including muscle weakness, myoclonus and myalgia. An important gene associated with Myositis is NARS1 (Asparaginyl-TRNA Synthetase 1), and among its related pathways/superpathways is tRNA Aminoacylation. The drugs Oseltamivir and Entecavir have been mentioned in the context of this disorder. Affiliated tissues include lung, skeletal muscle and bone, and related phenotypes are myositis and proximal muscle weakness

Disease Ontology : 12 A myopathy characterized by muscle inflammation.

NIH Rare Diseases : 52 Idiopathic inflammatory myopathy refers to a group of conditions that affect the skeletal muscles (muscles used for movement). Although the condition can be diagnosed at any age, idiopathic inflammatory myopathy most commonly occurs in adults between ages 40 and 60 years or in children between ages 5 and 15 years. Signs and symptoms of the condition include muscle weakness, joint pain and fatigue. There are several forms of idiopathic inflammatory myopathy, including polymyositis , dermatomyositis , and sporadic inclusion body myositis , which are each associated with unique features. As the name suggests, the cause of the condition is currently unknown (idiopathic). However, researchers suspect that it may occur due to a combination of genetic and environmental factors . Treatment is supportive and based on the signs and symptoms present in each person.

MedlinePlus : 42 Myositis means inflammation of the muscles that you use to move your body. An injury, infection, or autoimmune disease can cause it. Two specific kinds are polymyositis and dermatomyositis. Polymyositis causes muscle weakness, usually in the muscles closest to the trunk of your body. Dermatomyositis causes muscle weakness, plus a skin rash. Other symptoms of myositis may include Fatigue after walking or standing Tripping or falling Trouble swallowing or breathing Doctors may use a physical exam, lab tests, imaging tests and a muscle biopsy to diagnose myositis. There is no cure for these diseases, but you can treat the symptoms. Polymyositis and dermatomyositis are first treated with high doses of a corticosteroid. Other options include medications, physical therapy, exercise, heat therapy, assistive devices, and rest. NIH: National Institute of Neurological Disorders and Stroke

Wikipedia : 74 Myositis is inflammation or swelling of the muscles. Injury, medicines, infection, or an immune disorder... more...

More information from OMIM: 160750

Related Diseases for Myositis

Diseases in the Myositis family:

Bacterial Myositis Viral Myositis

Diseases related to Myositis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 953)
# Related Disease Score Top Affiliating Genes
1 inclusion body myositis 35.1 SERPINA3 HLA-B DYSF APP
2 myositis fibrosa 34.6 PIK3C2A MB
3 pyomyositis 33.8 PIK3C2A MB
4 dermatomyositis 33.8 TARS1 PIK3C2A IFIH1 GARS1
5 antisynthetase syndrome 33.2 TARS1 HARS1
6 exanthem 31.6 TRIM21 PIK3C2A IFIH1
7 childhood type dermatomyositis 31.6 TRIM21 PIK3C2A IFIH1 HARS1
8 encephalopathy, progressive, early-onset, with episodic rhabdomyolysis 31.5 PIK3C2A MB CHKB
9 myocarditis 31.4 PIK3C2A MB HLA-B DMD
10 autoimmune disease 31.4 TRIM21 TGM2 PSMB9 IFIH1 HLA-B FBL
11 giant cell myocarditis 31.1 MB HLA-B
12 muscular dystrophy 31.1 TTN PIK3C2A MB DYSF DMD CHKB
13 gas gangrene 31.0 SERPINA3 PIK3C2A MB DMD
14 compartment syndrome 31.0 PIK3C2A MB CHKB
15 adult dermatomyositis 31.0 IFIH1 CHKB
16 respiratory failure 31.0 TTN SERPINA3 PIK3C2A DMD
17 peripheral nervous system disease 30.9 TTN SERPINA3 GARS1 DMD APP
18 myoglobinuria 30.8 PIK3C2A MB DMD CHKB
19 limb-girdle muscular dystrophy 30.8 TTN DYSF DMD CAPN3
20 miyoshi muscular dystrophy 30.8 TTN PIK3C2A DYSF DMD CAPN3
21 facioscapulohumeral muscular dystrophy 1 30.7 TTN DYSF DMD CAPN3
22 muscular dystrophy, becker type 30.6 TTN PIK3C2A DYSF DMD CAPN3
23 muscular dystrophy, duchenne type 30.6 TTN PIK3C2A MB DMD CHKB
24 progressive muscular dystrophy 30.5 MB DMD
25 myofibrillar myopathy 30.5 TTN SERPINA3 DYSF DMD
26 neuromuscular disease 30.4 TTN SERPINA3 MB GARS1 DYSF DMD
27 localized lipodystrophy 30.3 DYSF DMD
28 dysferlinopathy 30.3 DYSF CAPN3
29 atrioventricular block 30.2 TTN TRIM21 PIK3C2A
30 muscular dystrophy-dystroglycanopathy , type c, 5 30.2 TTN DYSF CHKB CAPN3
31 anterior compartment syndrome 30.2 PIK3C2A MB DYSF
32 spinal muscular atrophy 30.2 GARS1 FBL DMD CAPN3
33 neuroleptic malignant syndrome 30.1 PIK3C2A MB CHKB
34 tibial muscular dystrophy 30.1 TTN DYSF DMD CAPN3
35 leiomyosarcoma 30.1 SERPINA3 PSMB9 MB
36 diffuse scleroderma 30.1 TRIM21 FBL
37 muscular dystrophy, limb-girdle, autosomal recessive 2 30.1 TTN DYSF DMD CAPN3
38 myopathy, congenital 30.1 TTN DYSF DMD CHKB
39 muscular dystrophy, congenital, lmna-related 30.0 TTN DYSF DMD CHKB
40 polyclonal hypergammaglobulinemia 29.9 TRIM21 SERPINA3
41 muscular disease 29.8 TTN TRIM21 SERPINA3 PIK3C2A MB IFIH1
42 congenital disorder of glycosylation, type iim 12.7
43 myositis ossificans 12.6
44 fibrodysplasia ossificans progressiva 12.5
45 focal myositis 12.5
46 infective myositis 12.4
47 viral myositis 12.4
48 bacterial myositis 12.4
49 fungal myositis 12.4
50 overlap myositis 12.4

Graphical network of the top 20 diseases related to Myositis:



Diseases related to Myositis

Symptoms & Phenotypes for Myositis

Human phenotypes related to Myositis:

31
# Description HPO Frequency HPO Source Accession
1 myositis 31 HP:0100614
2 proximal muscle weakness 31 HP:0003701

Symptoms via clinical synopsis from OMIM:

56
Muscle:
myositis
proximal muscle weakness

Clinical features from OMIM:

160750

UMLS symptoms related to Myositis:


muscle weakness, myoclonus, myalgia, back pain, torticollis, sciatica, muscle cramp, muscle rigidity, muscle spasticity

GenomeRNAi Phenotypes related to Myositis according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased hepcidin::fluc mRNA expression GR00253-A 9.23 AARS1 APP DMD DYSF GARS1 NARS1

MGI Mouse Phenotypes related to Myositis:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 muscle MP:0005369 9.28 AARS1 APP CAPN3 CHKB DMD DYSF

Drugs & Therapeutics for Myositis

Drugs for Myositis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 179)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Oseltamivir Approved Phase 4 196618-13-0, 204255-11-8 65028
2
Entecavir Approved, Investigational Phase 4 142217-69-4 153941
3
Telbivudine Approved, Investigational Phase 4 3424-98-4 159269
4
Simvastatin Approved Phase 4 79902-63-9 54454
5
Ezetimibe Approved Phase 4 163222-33-1 150311
6
Nicotinamide Approved, Investigational Phase 4 98-92-0 936
7
Atorvastatin Approved Phase 4 134523-00-5 60823
8
Folic acid Approved, Nutraceutical, Vet_approved Phase 4 59-30-3 6037
9
Melatonin Approved, Nutraceutical, Vet_approved Phase 4 73-31-4 896
10
Niacin Approved, Investigational, Nutraceutical Phase 4 59-67-6 938
11
Tenofovir Experimental, Investigational Phase 4 147127-20-6 464205
12 Anti-Infective Agents Phase 4
13 Anti-Retroviral Agents Phase 4
14 Antiviral Agents Phase 4
15 Reverse Transcriptase Inhibitors Phase 4
16 Anti-HIV Agents Phase 4
17 Protective Agents Phase 4
18 Antioxidants Phase 4
19 Central Nervous System Depressants Phase 4
20 Vitamin B Complex Phase 4
21 Vitamin B9 Phase 4
22 Folate Phase 4
23 Trace Elements Phase 4
24 Micronutrients Phase 4
25 Nutrients Phase 4
26 Vitamins Phase 4
27 Ezetimibe, Simvastatin Drug Combination Phase 4
28 Liver Extracts Phase 4
29 Vasodilator Agents Phase 4
30 Vitamin B3 Phase 4
31 Nicotinic Acids Phase 4
32 Hypolipidemic Agents Phase 4
33 Antimetabolites Phase 4
34 Lipid Regulating Agents Phase 4
35 Anticholesteremic Agents Phase 4
36 Hydroxymethylglutaryl-CoA Reductase Inhibitors Phase 4
37
Sirolimus Approved, Investigational Phase 2, Phase 3 53123-88-9 5284616 6436030 46835353
38
Miconazole Approved, Investigational, Vet_approved Phase 2, Phase 3 22916-47-8 4189
39
Everolimus Approved Phase 2, Phase 3 159351-69-6 6442177 70789204
40
Infliximab Approved Phase 2, Phase 3 170277-31-3
41
Methotrexate Approved Phase 3 1959-05-2, 59-05-2 126941
42
leucovorin Approved Phase 3 58-05-9 6006 143
43
Sargramostim Approved, Investigational Phase 3 123774-72-1, 83869-56-1
44
Lenograstim Approved, Investigational Phase 3 135968-09-1
45
Tadalafil Approved, Investigational Phase 3 171596-29-5 110635
46
Abatacept Approved Phase 3 332348-12-6 10237
47
belimumab Approved Phase 2, Phase 3 356547-88-1 5957 10451420
48
Sodium citrate Approved, Investigational Phase 3 68-04-2
49
Denosumab Approved Phase 3 615258-40-7
50
Risedronate Approved, Investigational Phase 3 105462-24-6 5245

Interventional clinical trials:

(show top 50) (show all 159)
# Name Status NCT ID Phase Drugs
1 Efficacy and Adverse Effect of Simvastatin Compare to Rosuvastatin in SLE Patients With Corticosteroid Therapy and High LDL Cholesterol Level Unknown status NCT00866229 Phase 4 Rosuvastatin;Simvastatin
2 Banlangen Granules Anti-seasonal Influenza Study: a Randomized, Double Blind, Positive and Placebo Controlled,Clinical Study. Unknown status NCT02232945 Phase 4 placebo of oseltamivir phosphate;oseltamivir phosphate;Banlangen (Radix Isatidis) granules;placebo of Banlangen(Radix Isatidis) granules
3 A Randomized, Prospective, Multicenter, Open-label Study to Evaluate the Efficacy of Telbivudine With or Without add-on Tenofovir According to Roadmap Strategy Compare With Entecavir in HBeAg-positive Chronic Hepatitis B Patients Unknown status NCT01588912 Phase 4 Telbivudine;Tenofovir;Entecavir
4 Effects of High Dose Simvastatin vs. Atorvastatin on Baseline Lipoprotein Profiles, Apo-A-1 and C Reactive Protein Unknown status NCT00736463 Phase 4 Simvastatin;Atorvastatin 80 mg
5 Rho-kinase in Patients With Atherosclerosis: Effects of Statins A Randomized Clinical Trial Comparing Ezetimibe/Simvastatin and Simvastatin Completed NCT00560170 Phase 4 Simvastatin (Zocor);10mg/10mg of Ezetimibe/Simvastatin (Vytorin)
6 The Effects of Melatonin on Elevated Liver Enzymes During Statins Treatment Completed NCT03121521 Phase 4 Melatonin 10 mg;Placebo
7 Magnetic Resonance Characterization of Carotid Atherosclerotic Plaque in Vivo: Effect of High Density Lipoprotein Elevation on Plaque Morphology Completed NCT00307307 Phase 4 Niacin/simvastatin compared to simvastatin alone at 2 doses
8 Double Blind, Prospective Randomized, Crossover Study of Patients With Muscle Complaints on Statin Therapy Terminated NCT00127335 Phase 4 cellulose placebo vs. atorvastatin
9 Anakinra in Patients With Refractory Idiopathic Inflammatory Myopathies Completed NCT01165008 Phase 2, Phase 3 Anakinra
10 A Randomized, Double-blind, Placebo-controlled, Multicenter, Parallel Group, Dose-finding, Pivotal, Phase 2b/3 Study to Evaluate the Efficacy, Safety, and Tolerability of Intravenous BYM338 at 52 Weeks on Physical Function, Muscle Strength, and Mobility and Additional Long Term Safety up to 2 Years in Patients With Sporadic Inclusion Body Myositis Completed NCT01925209 Phase 2, Phase 3 BYM338/bimagrumab;Placebo
11 Safety and Tolerability Trial of Arimoclomol for Sporadic Inclusion Body Myositis Completed NCT00769860 Phase 2, Phase 3 Arimoclomol
12 Étude de l'Effet de la Rapamycine Sur la Force Musculaire et la réponse Immunitaire au Cours de la Myosite à Inclusions: étude RAPAMI" Completed NCT02481453 Phase 2, Phase 3 Rapamycin;Placebo
13 An Open Trial With TNF Blockade With Infliximab (Remicade®), in Patients With Chronic Inflammatory Myopathies Completed NCT00443222 Phase 2, Phase 3 Infliximab
14 An Open-label, Long-term Study to Evaluate the Safety and Tolerability of BYM338 in Patients With Sporadic Inclusion Body Myositis Completed NCT02250443 Phase 2, Phase 3 BYM338 (Bimagrumab)
15 Extension of the CBYM338B2203 Phase IIb/III Study to Evaluate the Long-term Efficacy, Safety and Tolerability of Intravenous BYM338 in Patients With Sporadic Inclusion Body Myositis Completed NCT02573467 Phase 3 Bimagrumab;Placebo
16 Six Month Clinical Research Study for Patients With Moderate or Severe Dry Eye Syndrome Completed NCT00025818 Phase 3 Ophthalmic Emulsion
17 A Prospective, Randomised, Assessor-blind, Multicenter Study of Efficacy and Safety of Combined Treatment of Methotrexate + Glucocorticoids Versus Glucocorticoids Alone in Patients With Polymyositis and Dermatomyositis. Completed NCT00651040 Phase 3 Prednisone;Methotrexate
18 Clinical Trial of CoQ10 for Mild-to-Moderate Statin-Associated Muscle Symptoms Completed NCT01032993 Phase 2, Phase 3
19 Effect of 80-mg Atorvastatin on Myocardial Edema Following Coronary Artery Bypass Surgery in Relation With Follistatin-Like Protein-1 Completed NCT02901379 Phase 3 Atorvastatin 80mg;Atorvastatin 10mg
20 High Dose Cyclophosphamide for Treatment of Systemic Sclerosis (Scleroderma) Completed NCT00501995 Phase 3 IV Cyclophosphamide
21 A Double Blind Randomized Control Trial of Tadalafil in Interstitial Lung Disease of Scleroderma Completed NCT01553981 Phase 3 Tadalafil;Placebo
22 High-dose Simvastatin for Aneurysmal Subarachnoid Haemorrhage: Is it Better? Completed NCT01077206 Phase 2, Phase 3 Simvastatin
23 A Phase 3, Randomized, Double-Blind Clinical Trial to Evaluate the Efficacy and Safety of Abatacept SC With Standard Treatment Compared to Standard Treatment Alone in Improving Disease Activity in Adults With Active Idiopathic Inflammatory Myopathy (IIM) Recruiting NCT02971683 Phase 3 Abatacept subcutaneous;Placebo
24 A Randomized, Double Blind Controlled Trial Comparing Rituximab Against Intravenous Cyclophosphamide in Connective Tissue Disease Associated Interstitial Lung Disease Recruiting NCT01862926 Phase 2, Phase 3 Rituximab;Cyclophosphamide
25 Belimumab for Maintenance Therapy in Idiopathic Inflammatory Myositis Active, not recruiting NCT02347891 Phase 2, Phase 3 Belimumab;Placebo
26 MOVE TRIAL: A Phase 3, Efficacy and Safety Study of Oral Palovarotene for the Treatment of Fibrodysplasia Ossificans Progressiva (FOP) Active, not recruiting NCT03312634 Phase 3 Palovarotene
27 An Open-label, Non-randomized Trial to Investigate the Efficacy and Safety of Early Versus Delayed Start of Arimoclomol in Patients With Sporadic Inclusion Body Myositis Who Have Completed the IBM4809 Trial Enrolling by invitation NCT04049097 Phase 3 Arimoclomol
28 Efficacy of Denosumab and Zoledronic Acid in the Treatment of Idiopathic Inflammatory Myopathies Related Reduced Bone Mineral Density: a Prospective Controlled Trial Not yet recruiting NCT04034199 Phase 3 Denosumab;Zoledronic Acid
29 Intraorbital Injection Versus Oral Steroid in Patients With Anterior Idiopathic Orbital Inflammation: A Randomized Clinical Trial Not yet recruiting NCT03958344 Phase 3 Prednisolone;Triamcinolone + Betamethason
30 Cyclophosphamide and Azathioprine vs Tacrolimus in Antisynthetase Syndrome-related Interstitial Lung Disease : Multicentric Randomized Phase III Trial Not yet recruiting NCT03770663 Phase 3 Cyclophosphamide and azathioprine;Tacrolimus
31 Rituximab Therapy in Refractory Adult and Juvenile Idiopathic Inflammatory Myopathy (IIM) Completed NCT00106184 Phase 2 Rituximab;Placebo
32 A Double-blind, Placebo-controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of BYM338 in Patients With Sporadic Inclusion Body Myositis Completed NCT01423110 Phase 2
33 Effects of a T Cell-Depleting Monoclonal Antibody, Alemtuzumab, in Patients With Inclusion Body Myositis: A Pilot Clinicopathological Study Completed NCT00079768 Phase 2 Alemtuzumab (Campath)
34 A Phase 2 Open-label Study to Evaluate the Long-term Safety of Sifalimumab in Adult Subjects With Systemic Lupus Erythematosus or Myositis Completed NCT00979654 Phase 2 Sifalimumab
35 Tocilizumab in the Treatment of Refractory Polymyositis and Dermatomyositis Completed NCT02043548 Phase 2 tocilizumab;placebo
36 The Efficacy of High-Dose Intravenous Immunoglobulin in Patients With Inflammatory Myopathies: A Three Month Randomized Trial With Option for Cross-Over Completed NCT00001261 Phase 2 Gamma Globulin
37 FORCE: Rituximab (CD 20+-B Cell-depleting Monoclonal Antibody) for the Treatment of Refractory Inflammatory Myopathies With Specific Antibodies and Refractory Myasthenia Gravis Completed NCT00774462 Phase 2 Rituximab
38 Statins and Lupus: Effects of Statins on Clinical Lupus Parameters, Serological Markers and Toll-like Receptors. Completed NCT00519363 Phase 1, Phase 2 atorvastatin
39 A Phase 2 Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study of a RARγ-Specific Agonist (Palovarotene) in the Treatment of Preosseous Flare-ups in Subjects With Fibrodysplasia Ossificans Progressiva (FOP) Completed NCT02190747 Phase 2 Palovarotene;Placebo
40 The Effects of High Dose Fish Oil Supplementation on Delayed Onset Muscle Soreness and Inflammatory Markers Completed NCT00805870 Phase 2 Lovaza (omega-3-acid ethyl esters);Wheat Germ Oil
41 A Double-blind, Randomized Study to Evaluate the Efficacy and Safety of TAK-475 or Placebo When Coadministered With Fenofibrate in Subjects With Combined Hyperlipidemia Completed NCT00813527 Phase 2 Lapaquistat acetate and fenofibrate;Fenofibrate
42 Novel Drug Delivery of Sodium Thiosulfate for Calcinosis Associated With Adult and Juvenile Dermatomyositis Completed NCT01572844 Phase 2 Sodium thiosulfate
43 A Pilot Study of the Role of Methimazole in Patients With Polymyositis and Dermatomyositis Completed NCT00001421 Phase 2 methimazole
44 Open Label Proof of Concept Study to Evaluate Efficacy and Safety of Adrenocorticotropic Hormone Gel in Refractory Dermatomyositis or Polymyositis Completed NCT01906372 Phase 2 Adrenocorticotropic Hormone Gel
45 A Randomized, Third-Party-Blind, Placebo-Controlled Pilot Study of the Effect of h5G1.1-mAb on Dermatomyositis Patients Completed NCT00005571 Phase 2 h5G1.1-mAb
46 Phase II Clinical Trial to Examine the Efficacy and Safety of Dutasteride in Patients With Kennedy's Disease (Spinal and Bulbar Muscular Atrophy) Completed NCT00303446 Phase 2 Dutasteride;Placebo
47 A Randomized, Double-Blind, Placebo-Controlled Trial of Infliximab in Patients With Dermatomyositis and Polymyositis Completed NCT00033891 Phase 2 Infliximab
48 A Phase 2 Randomized, Double-blind, Placebo-controlled, Crossover Multicenter Study to Evaluate the Safety and Efficacy of KZR-616 in the Treatment of Patients With Active Polymyositis or Dermatomyositis Recruiting NCT04033926 Phase 2 KZR-616;Placebo
49 An Open-label Study of Sodium Thiosulfate for Treatment of Calcinosis Associated With Juvenile and Adult Dermatomyositis Recruiting NCT03267277 Phase 2 Sodium Thiosulfate
50 A Randomized, Controlled Pilot Trial to Evaluate the Efficacy and Safety of Subcutaneous Abatacept in Treating Interstitial Lung Disease Associated With the Anti-synthetase Syndrome Recruiting NCT03215927 Phase 2 Abatacept

Search NIH Clinical Center for Myositis

Inferred drug relations via UMLS 71 / NDF-RT 50 :


Carisoprodol
Chlorphenesin
chlorphenesin carbamate
Chlorzoxazone
cyclobenzaprine
Cyclobenzaprine hydrochloride
metaxalone
Methocarbamol
Orphenadrine
Orphenadrine Citrate
Orphenadrine Hydrochloride
tizanidine
tizanidine hydrochloride

Cochrane evidence based reviews: myositis

Genetic Tests for Myositis

Genetic tests related to Myositis:

# Genetic test Affiliating Genes
1 Myositis 29

Anatomical Context for Myositis

MalaCards organs/tissues related to Myositis:

40
Lung, Skeletal Muscle, Bone, T Cells, Skin, Heart, Testes

Publications for Myositis

Articles related to Myositis:

(show top 50) (show all 9163)
# Title Authors PMID Year
1
Intracranial actinomycosis of odontogenic origin masquerading as auto-immune orbital myositis: a fatal case and review of the literature. 61 42
31477035 2019
2
Myositis in clinical practice-relevance of new antibodies. 61 42
31427061 2018
3
Calcinosis in Juvenile Dermatomyositis. 42
31618543 2019
4
Increased BACE1 mRNA and noncoding BACE1-antisense transcript in sporadic inclusion-body myositis muscle fibers--possibly caused by endoplasmic reticulum stress. 54 61
20236612 2010
5
Gemfibrozil-induced myositis in a patient with normal renal function. 54 61
19934390 2010
6
Serum cardiac troponin T, but not troponin I, is elevated in idiopathic inflammatory myopathies. 54 61
19833747 2009
7
Sera from anti-Jo-1-positive patients with polymyositis and interstitial lung disease induce expression of intercellular adhesion molecule 1 in human lung endothelial cells. 54 61
19644880 2009
8
Increased serum levels of B cell activating factor (BAFF) in subsets of patients with idiopathic inflammatory myopathies. 54 61
18628284 2009
9
Eosinophilic myositis in calpainopathy: could immunosuppression of the eosinophilic myositis alter the early natural course of the dystrophic disease? 54 61
19285864 2009
10
[Hypothyroidism with leading myopathy in a patient suffering from systemic lupus erythematosus and Hashimoto's thyroiditis]. 54 61
18936898 2008
11
Major histocompatibility complex class I expression can be used as a diagnostic tool to differentiate idiopathic inflammatory myopathies from dystrophies. 54 61
18974565 2008
12
Distal inflammatory myopathy: unusual presentation of polymyositis or new entity? 54 61
18534849 2008
13
Interrelation of inflammation and APP in sIBM: IL-1 beta induces accumulation of beta-amyloid in skeletal muscle. 54 61
18420712 2008
14
Adults with eosinophilic myositis and calpain-3 mutations. 54 61
18299526 2008
15
Transcriptional explorations of CAPN3 identify novel splicing mutations, a large-sized genomic deletion and evidence for messenger RNA decay. 54 61
17979987 2007
16
NOGO is increased and binds to BACE1 in sporadic inclusion-body myositis and in A beta PP-overexpressing cultured human muscle fibers. 54 61
17764014 2007
17
Limited effects of high-dose intravenous immunoglobulin (IVIG) treatment on molecular expression in muscle tissue of patients with inflammatory myopathies. 54 61
17277004 2007
18
[Is every case of muscle damage during hypolipemic therapy the side effect of this therapy? A case report]. 54 61
18320790 2007
19
Rituximab for refractory polymyositis: an open-label prospective study. 54 61
17722224 2007
20
Anti-Jo-1 antibody levels correlate with disease activity in idiopathic inflammatory myopathy. 54 61
17763431 2007
21
Statin and statin-fibrate use was significantly associated with increased myositis risk in a managed care population. 54 61
17606177 2007
22
Novel conformation of histidyl-transfer RNA synthetase in the lung: the target tissue in Jo-1 autoantibody-associated myositis. 54 61
17665459 2007
23
Major histocompatibility complex class I and II detection as a diagnostic tool in idiopathic inflammatory myopathies. 54 61
17616993 2007
24
Interferon-gamma and interleukin-4 gene polymorphisms in Caucasian idiopathic inflammatory myopathy patients in UK. 54 61
17405833 2007
25
Myostatin precursor protein is increased and associates with amyloid-beta precursor protein in inclusion-body myositis culture model. 54 61
17359364 2007
26
Inducible overexpression of wild-type prion protein in the muscles leads to a primary myopathy in transgenic mice. 54 61
17420473 2007
27
Expression of major histocompatibility complex class I and class II antigens in canine masticatory muscle myositis. 54 61
17360184 2007
28
Genetic determinants of statin intolerance. 54 61
17376224 2007
29
Immunolocalization of interleukin-1 receptors in the sarcolemma and nuclei of skeletal muscle in patients with idiopathic inflammatory myopathies. 54 61
17265504 2007
30
MyoD expression restores defective myogenic differentiation of human mesoangioblasts from inclusion-body myositis muscle. 54 61
17077152 2006
31
Elevated levels of amyloid precursor protein in muscle of patients with amyotrophic lateral sclerosis and a mouse model of the disease. 54 61
16856153 2006
32
HMG-CoA-reductase inhibitors and neuropathy: reports to the Netherlands Pharmacovigilance Centre. 54 61
17057271 2006
33
Presymptomatic neuromuscular disorders disclosed following statin treatment. 54 61
16864763 2006
34
Parkin and its association with alpha-synuclein and AbetaPP in inclusion-body myositis and AbetaPP-overexpressing cultured human muscle fibers. 54 61
17039976 2006
35
CAPN3 mutations in patients with idiopathic eosinophilic myositis. 54 61
16607617 2006
36
Neurological manifestations of dengue virus infection. 54 61
16524594 2006
37
Serum creatine kinase levels and renal function measures in exertional muscle damage. 54 61
16679975 2006
38
Difference in adhesion molecule expression (ICAM-1 and VCAM-1) in juvenile and adult dermatomyositis, polymyositis and inclusion body myositis. 54 61
16431335 2006
39
Antisynthetase syndrome associated with sarcoidosis. 54 61
17043379 2006
40
Damage and inflammation in muscular dystrophy: potential implications and relationships with autoimmune myositis. 54 61
16224247 2005
41
Role of major histocompatibility complex class I molecules in autoimmune myositis. 54 61
16224250 2005
42
Mdm muscular dystrophy: interactions with calpain 3 and a novel functional role for titin's N2A domain. 54 61
16115818 2005
43
Myostatin is increased and complexes with amyloid-beta within sporadic inclusion-body myositis muscle fibers. 54 61
15983828 2005
44
Treatment of antisynthetase-associated interstitial lung disease with tacrolimus. 54 61
16052580 2005
45
Safety and efficacy of rosuvastatin therapy for the prevention of hyperlipidemia in adult cardiac transplant recipients. 54 61
16102434 2005
46
Beta-chemokine receptor expression in idiopathic inflammatory myopathies. 54 61
15772970 2005
47
Benign acute childhood myositis. 54 61
15973022 2005
48
Changes of single fiber electromyography in patients with inflammatory myopathies. 54 61
15844301 2005
49
Expression of the beta chemokines CCL3, CCL4, CCL5 and their receptors in idiopathic inflammatory myopathies. 54 61
15634233 2005
50
Do tissue levels of autoantigenic aminoacyl-tRNA synthetase predict clinical disease? 54 61
16085368 2005

Variations for Myositis

ClinVar genetic disease variations for Myositis:

6 ‎‎
# Gene Name Type Significance ClinVarId dbSNP ID GRCh37 Pos GRCh38 Pos
1 FAM111B NM_198947.4(FAM111B):c.1462del (p.Cys488fs)deletion Likely pathogenic 599012 rs1565191262 11:58893032-58893032 11:59125559-59125559

Expression for Myositis

Search GEO for disease gene expression data for Myositis.

Pathways for Myositis

Pathways related to Myositis according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Show member pathways
11.26 TARS1 NARS1 HARS1 GARS1 AARS1

GO Terms for Myositis

Cellular components related to Myositis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytoplasm GO:0005737 10.1 TTN TRIM21 TGM2 TARS1 PSMB9 PIK3C2A
2 cytosol GO:0005829 9.86 TTN TRIM21 TGM2 TARS1 PSMB9 PIK3C2A
3 extracellular exosome GO:0070062 9.47 TTN TGM2 TARS1 SERPINA3 PSMB9 PIK3C2A
4 astrocyte projection GO:0097449 9.16 DMD APP

Biological processes related to Myositis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 muscle organ development GO:0007517 9.43 DMD CHKB CAPN3
2 translation GO:0006412 9.35 TARS1 NARS1 HARS1 GARS1 AARS1
3 muscle fiber development GO:0048747 9.32 DYSF DMD
4 tRNA aminoacylation GO:0043039 9.16 TARS1 AARS1
5 tRNA aminoacylation for protein translation GO:0006418 9.02 TARS1 NARS1 HARS1 GARS1 AARS1

Molecular functions related to Myositis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 ATP binding GO:0005524 9.81 TTN TARS1 PIK3C2A NARS1 IFIH1 HARS1
2 structural constituent of muscle GO:0008307 9.43 TTN DMD CAPN3
3 ligase activity GO:0016874 9.35 TARS1 NARS1 HARS1 GARS1 AARS1
4 aminoacyl-tRNA ligase activity GO:0004812 9.02 TARS1 NARS1 HARS1 GARS1 AARS1

Sources for Myositis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....